Search

Displaying results 1811 - 1820 of 5900 in total
  1. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma. … CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells.

  2. Drug

    Fluoride ion F-18

    go.drugbank.com/drugs/DB09398
    ApprovedInvestigational

    No adverse reactions have been reported. … Sodium Fluoride F 18 Injection is a positron emitting radiopharmaceutical, no-carrier added.

  3. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected

  4. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [L50908] It consists of two heavy chains (451 amino acid residues each) and two light chains (217 amino acid residues each). … [L50933] Unlike other complement inhibitors previously approved for PNH, crovalimab uses a mechanism called anti-C5 sequential monoclonal antibody recycling technology that allows the drug to bind to

  5. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. … Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass.

  6. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  7. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … [A4033] Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.

  8. Drug

    Phenylbutyric acid

    go.drugbank.com/drugs/DB06819
    ApprovedInvestigational

    [A249035] It is used to treat genetic metabolic syndromes, neuropathies, and urea cycle disorders.[L386,L42105]

  9. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes....

  10. Drug

    Pomalidomide

    go.drugbank.com/drugs/DB08910
    ApprovedInvestigational

    Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.